In this Program Project renewal application, the applicant group is representative of three primary institutions, The Ohio State University (OSU), the University of Illinois at Chicago (UIC), and the University of North Carolina at Greensboro (UNCG). The participants have combined their vast experience in the isolation, structure elucidation, and biological evaluation of natural products, to the development of a consolidated, integrated program for the discovery of novel anticancer agents of diverse origin for development as cancer chemotherapeutic agents. Plant materials to be studied in Project 1 (OSU) will be collected by established botanists located in tropical countries with the assistance of the NAPRALERT database (Project 2; UIC), and lichens and their fungal associates (Project 1), cyanobacteria (Project 2) and filamentous fungi (Project 3; UNCG) will also be accessed. Organisms acquired will be extracted and evaluated in a diverse battery of relevant mechanism-based, cell-based, and tumor-growth related assays currently operational at OSU (Project 1), UIC (Core 1), Columbia University (through Project 3), and via other external collaborators (through Core A at OSU). Dereplication of known active compounds will be accomplished at OSU, UIC, and UNCG using computerized literature surveys and LC-MS coupled to bioassays. Bioassay-directed fractionation will be employed in Projects 1-3 for the elucidation of the active principles. Lead development of active natural products via medicinal chemistry and pharmacokinetics-related studies will be conducted at OSU (Core 2), facilitated by the OSU Biostatistics group (Core A). Novel, active compounds thus discovered will be further evaluated in our panel of in vitro and in vivo bioassays (Projects 1 and 3, Core A, and some external collaborators). Group decisions will be made regarding the further development of agents for potential use as anticancer agents. The more advanced stages of biological and toxicological testing will be aided through consultation with the Drug Discovery Institute of the OSU Comprehensive Cancer Center (through Core A). The Consortium will work with the involvement of the NCI Program Official in the discovery process, and plans to hold regular meetings of key scientific personnel (inclusive of our External and OSU Internal Scientific Advisory Boards) to enhance communication and decision- making processes, to be organized by Core A. Excellent facilities for the isolation, structure determination, chemical modification, synthesis, and in vitro and in vivo biological evaluation, and overall project data management are available. The overarching goal of this P01 is to identify lead compounds that ultimately have therapeutic value for the treatment of cancer.

Public Health Relevance

Cancer is responsible for about one in every four deaths in the United States, and new treatments are urgently needed. It is the overall goal of the integrated studies in this renewal application to discover novel chemicals from selected tropical rainforest plants, as well as lichens, cyanobacteria and fungi, for development as cancer chemotherapeutic agents, particularly for tumors not cured by current treatment methods.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA125066-11A1
Application #
9855591
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Fu, Yali
Project Start
2007-07-01
Project End
2025-04-30
Budget Start
2020-05-15
Budget End
2021-04-30
Support Year
11
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
Schools of Pharmacy
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Crnkovic, Camila M; Krunic, Aleksej; May, Daniel S et al. (2018) Calothrixamides A and B from the Cultured Cyanobacterium Calothrix sp. UIC 10520. J Nat Prod 81:2083-2090
Wilson, Tyler A; Tokarski 2nd, Robert J; Sullivan, Peter et al. (2018) Total Synthesis of Scytonemide A Employing Weinreb AM Solid-Phase Resin. J Nat Prod 81:534-542
Lu, Chunwan; Yang, Dafeng; Sabbatini, Maria E et al. (2018) Contrasting roles of H3K4me3 and H3K9me3 in regulation of apoptosis and gemcitabine resistance in human pancreatic cancer cells. BMC Cancer 18:149
El-Elimat, Tamam; Rivera-Chávez, José; Burdette, Joanna E et al. (2018) Cytotoxic homoisoflavonoids from the bulbs of Bellevalia flexuosa. Fitoterapia 127:201-206
Ren, Yulin; Anaya-Eugenio, Gerardo D; Czarnecki, Austin A et al. (2018) Cytotoxic and NF-?B and mitochondrial transmembrane potential inhibitory pentacyclic triterpenoids from Syzygium corticosum and their semi-synthetic derivatives. Bioorg Med Chem 26:4452-4460
Crnkovic, Camila M; May, Daniel S; Orjala, Jimmy (2018) The impact of culture conditions on growth and metabolomic profiles of freshwater cyanobacteria. J Appl Phycol 30:375-384
Woodard, John L; Huntsman, Andrew C; Patel, Pratiq A et al. (2018) Synthesis and antiproliferative activity of derivatives of the phyllanthusmin class of arylnaphthalene lignan lactones. Bioorg Med Chem 26:2354-2364
Ren, Yulin; Gallucci, Judith C; Li, Xinxin et al. (2018) Crystal Structures and Human Leukemia Cell Apoptosis Inducible Activities of Parthenolide Analogues Isolated from Piptocoma rufescens. J Nat Prod 81:554-561
May, Daniel S; Kang, Hahk-Soo; Santarsiero, Bernard D et al. (2018) Ribocyclophanes A-E, Glycosylated Cyclophanes with Antiproliferative Activity from Two Cultured Terrestrial Cyanobacteria. J Nat Prod 81:572-578
Oblinger, Janet L; Burns, Sarah S; Huang, Jie et al. (2018) Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation. Exp Neurol 299:299-307

Showing the most recent 10 out of 144 publications